- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:30 | Bioaffinity Technologies stock soars after lung cancer test aids early detection | 10 | Investing.com | ||
| Do | bioAffinity Technologies, Inc. - S-1/A, General form for registration of securities | 2 | SEC Filings | ||
| 17.09. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| BIOAFFINITY TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 17.09. | bioAffinity Technologies to implement 1-for-30 reverse stock split | 2 | Investing.com | ||
| 17.09. | bioAffinity Technologies kündigt Aktienzusammenlegung im Verhältnis 1:30 an | 3 | Investing.com Deutsch | ||
| 17.09. | bioAffinity Technologies Announces 1-for-30 Reverse Stock Split Effective at the Open of Trading on September 19, 2025 | 108 | Business Wire | SAN ANTONIO, Texas--(BUSINESS WIRE)--bioAffinity Technologies, Inc. (NASDAQ: BIAF, BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer,... ► Artikel lesen | |
| 13.09. | bioAffinity Technologies, Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 09.09. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 02.09. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.08. | BioAffinity Technologies files to sell 12.61M shares of common stock for holders | 1 | Seeking Alpha | ||
| 29.08. | bioAffinity Technologies, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 18.08. | bioAffinity Technologies appoints two new directors to board | 1 | Investing.com | ||
| 14.08. | bioAffinity Technologies, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | bioAffinity Technologies GAAP EPS of -$0.17, revenue of $1.3M | 1 | Seeking Alpha | ||
| 13.08. | bioAffinity Technologies, Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 13.08. | bioAffinity Technologies raises $1.2 million in private placement | 4 | Investing.com | ||
| 13.08. | bioAffinity Technologies announces pricing of private placement | 1 | Seeking Alpha | ||
| 31.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | bioAffinity Technologies, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 22.07. | bioAffinity Technologies sichert sich kanadisches Patent für Lungenkrebstest | 4 | Investing.com Deutsch |
1 2 3 Weiter >>
49 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | - | - | Palatin Technologies, Inc.: Palatin Earns €5.5 Million ($6.5 Million) Milestone Payment in Retinal Disease Collaboration with Boehringer Ingelheim | Collaboration focused on developing potential first-in-class melanocortin receptor targeted treatment for patients with diabetic retinopathy, including diabetic... ► Artikel lesen | |
| BIOXXMED | 0,120 | 0,00 % | PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025 | DJ PTA-Adhoc: bioXXmed AG: Ergebnis für das Geschäftsjahr 2024 - Prognose für das Geschäftsjahr 2025
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR
bioXXmed AG: Ergebnis für... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| OCUGEN | 1,255 | -3,46 % | Ocugen plant drei Zulassungsanträge für Gentherapien gegen Erblindung bis 2028 | ||
| SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem Corp.: Sirona Biochem Update to Shareholders on Financial Status and Operations | VANCOUVER, British Columbia, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) ("Sirona") wishes to provide shareholders with a critical update on the company's financial... ► Artikel lesen | |
| BIO-GATE | 0,960 | -5,88 % | Bio-Gate platziert Kapitalerhöhung über 836.059 neue Aktien | Die Bio-Gate AG hat eine Barkapitalerhöhung aus genehmigtem Kapital beschlossen und umgesetzt. Das Grundkapital wird von 9.243.691 Euro um 836.059 Euro auf 10.079.750 Euro erhöht. Dazu werden 836.059... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,500 | +5,49 % | Defence Therapeutics Inc.: Defence's Director, Strategy & Business Advisor Dr. Amie Phinney Discusses the Accum Platform on Money Talk Radio with Ellis Martin | Montreal, Quebec--(Newsfile Corp. - September 23, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company specialized in... ► Artikel lesen | |
| VAXART | 0,295 | -1,67 % | Vaxart, Inc.: Vaxart Announces Withdrawal of Reverse Stock Split Proposal | SOUTH SAN FRANCISCO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,400 | -6,04 % | Burcon NutraScience Corporation: Burcon Announces New Board Members and Results of Shareholder Meeting | Vancouver, British Columbia--(Newsfile Corp. - September 17, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) (the "Burcon" or the "Company"), a global technology leader in plant-based... ► Artikel lesen | |
| IDORSIA | 3,925 | -1,75 % | Idorsia Pharmaceuticals Ltd: Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China | Allschwil, Switzerland - September 22, 2025Idorsia Ltd. (SIX: IDIA) announces that Simcere Pharmaceuticals Group Ltd (2096.HK, "Simcere") has launched QUVIVIQ® (daridorexant) in China. QUVIVIQ, Idorsia's... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 5,710 | -0,87 % | Cellectar Biosciences, Inc.: Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) | ||
| AFFIMED | 0,972 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 28.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 28.05.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 28.05.2025ISIN NameBMG3728V1090 GAN... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,073 | -100,00 % | AIM ImmunoTech Inc.: AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen (Rintatolimod) with Checkpoint Inhibitors | Patent supports AIM's strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical... ► Artikel lesen | |
| IMMUNIC | 0,780 | +1,83 % | EQS-News: Immunic AG: Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple Sclerosis | Issuer: Immunic AG
/ Key word(s): Conference/Study results
Immunic Presented Key Vidofludimus Calcium Data at the 41st Congress of ECTRIMS, Highlighting Its Potential in Multiple... ► Artikel lesen | |
| T2 BIOSYSTEMS | 0,250 | 0,00 % | NSE/A - T2 Biosystems, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities |
BIOAFFINITY TECHNOLOGIES INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von +2,600 (+76,25 %) liegt der Kurs bei 6,010 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOAFFINITY TECHNOLOGIES INC finden Sie auf Wallstreet Online.